TEHRAN (Dispatches) – Iranian Health Minister Seyed Hassan Qazizadeh Hashemi on Tuesday unveiled three new domestically made medicines: two blood glucose-lowering drugs and a new type of antihistamine.
In a ceremony, Qazizadeh Hashemi unveiled the mass production of "Neotadine”, the newest second-generation antihistamine approved by the FDA, in Dr. Abidi Pharmaceutical Laboratory in Tehran.
Two blood glucose-lowering drugs, namely Gloripa and Sinoripa, were also unveiled during the ceremony.  
Gloripa is the first medicine used to decrease blood glucose levels, which can dramatically lower chances of death resulting from cardiovascular diseases. It also prevents the progression of diabetes-related kidney disease.
Sinoripa also lowers blood sugar levels. The medicine is a mixture of two blood drugs in the form of tablets.
Iranian experts have in recent years made great headways in using modern medical technology to cure a broad range of diseases inside the country, making Iran a top destination for medical tourism.
Back in 2015, Iran unveiled a rare drug named "Sitagliptin” that treats diabetes type 2 and has been produced by the country’s medical experts under the trade name "Ziptin”.
Previously, a German company had a monopoly on the drug, but Iran broke the monopoly by launching the production line of the medicine.
And also, an Iranian knowledge-based company has managed to produce a new type of nano-medicine for treatment of various types of cancer and is exporting it to regional countries.
Dr Navid Goudarzi, the head of the pharmaceutical company, says his firm has managed to produce a cancer treatment drug which used to be imported to the country before.
"The team was engaged in five years of research to develop the drug which is called Paclitaxel,” he said, adding that the drug has been produced using nanotechnology.
Speaking in an interview with Mehr News Agency, he said Paclitaxel can be used to treat pancreatic, breast, lung, stomach, and ovarian cancers.
He noted that the medicine was developed on the basis of a technology known as albumin-binding nanoparticles.